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Endometriosis is a benign disease with high prevalence in women of reproductive age esti-
mated between 10 and 15% and is associated with considerable morbidity. Its etiology and
pathogenesis are controversial but it is believed to involve multiple genetic, environmental,
immunological, angiogenic, and endocrine processes. Altered expressions of growth fac-
tors, cytokines, adhesion molecules, matrix metalloproteinases, and enzymes for estrogen
synthesis and metabolism have been frequently observed in this condition.The possibility
of genetic basis of endometriosis is demonstrated in studies of familial disease, in which
the incidence of endometriosis is higher for first-degree relatives of probands as com-
pared to controls. This review describes mainly the cellular, cytochemical, cytogenetic,
and molecular genetic features of endometriotic lesions and cultured endometriotic cells.
In attempts to identify candidate gene (s) involved in the pathogenesis of endometrio-
sis, a tissue-based approaches including conventional cytogenetics (RHG-banding), loss of
heterozygosity (LOH), and comparative genomic hybridization (CGH) were employed. In
addition to the karyotypic anomalies, consistent chromosome instability was confirmed by
CGH and fluorescence in situ hybridization (FISH).The nature and significance of the mole-
cular genetic aberrations in relation to the locations and function of oncogenes and tumor
suppressor genes will be discussed. At last, a possible pathogenic role of embryonic duct
remnants was observed in seven female fetal reproductive tract in endometriosis and may
induce a discussion about the beginning of ovarian tumors and malignant proliferations.
Keywords: endometriosis, permanent cell line, chromosome, comparative genomic hybridization, fluorescence
in situ hybridization, embryonic duct remnants
INTRODUCTION
Endometriosis is a common gynecological disorder accounting
for 10–15% of pelvic pain and infertility in women of reproduc-
tive age. Despite its prevalence, relatively little is known about the
underlying pathophysiological mechanisms. Numerous studies
however suggest that it has a multidimensional etiology including,
hereditary, hormonal, and immunological factors (1, 2).
This condition is considered as benign disorder, but exhibits
cellular proliferation, cellular invasion, and neo angiogenesis.
The glandular epithelium occasionally exhibits cytological atypia
and/or hyperplasia (3) as well as DNA aneuploidy (4). The malig-
nant potential of the endometriotic epithelial cells has been sug-
gested in some cases considering the monoclonal methylation
pattern of the HUMARA alleles and their invasive and metastatic
ability in vitro (5, 6). In this context, previous studies supported
the hypothesis that progression of endometriotic lesions to frank
malignancy can occur although with a very rare incidence (7–11).
However, the significance of the so-called malignant potential of
endometriotic cells is controversial since monoclonal cells growth
pattern was described in various benign lesions (5).
It is difficult to obtain direct evidence for mechanistic events
in endometriosis for a variety of reasons. One is a lack of experi-
mental models that adequately mimic in situ conditions. Animal
models of endometriosis, exist including monkey and mouse sys-
tems (12, 13), but at present it is not known how closely the
disease in animals mimics the human disease. More informa-
tion critical to the understanding of pathogenesis and treatment
of endometriosis will possibly come from studies of controlled
in vitro cell models. Cell culture allows the study of cell spe-
cific characteristics of endometriotic tissues compared to epithe-
lial and stromal cells from normal endometrium. Such cellular
systems will permit the investigation of regulatory mechanisms
controlling steroid hormone receptors expression and cytokine
and growth factor secretion, which have been postulated to dif-
fer between cells from normal endometrium and endometriotic
lesions (14–18).
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ENDOMETRIOTIC CELL GROWTH AND DIFFERENTIATION
There is strong evidence that the endometrium of women with
endometriosis has an increased capacity to proliferate, implant,
and grow in the peritoneal cavity (2). Morphological studies of
tissue sections have demonstrated that the endometriotic glands
have a wide range of morphologic development presenting a
pattern ranging from poorly to highly differentiated glandular
structures. Such morphological variations occur from gland to
gland even within cellular areas in the same gland (19). Adequate
morphological changes of the endometriotic glands were found
in implants only during the proliferative phase of the menstrual
cycle, whereas secretory changes were completely missing during
the luteal phase (19). These changes include histological differen-
tiation and induction of secretory proteins such as prolactin (PRL)
(20), insulin-like growth factor binding protein-1 (IGF-BP1) (21),
and extracellular matrix proteins such as fibronectin (22). In addi-
tion, several markers are aberrantly expressed in endometriotic
cells in comparison to the normal cell elements, including the
gap junction connexins (Cx) (23), β-cadherins (24), metallopro-
teinases (25), and P450 aromatase (26). Altogether, these features
indicate a high degree of dedifferentiation in comparison to the
normal situation.
The regulatory mechanisms involved in morphological and
biochemical differentiation of uterine endometrium are obvi-
ously complex (27, 28). It is widely accepted that endometrial
stromal cells are essential for proliferation, morphogenesis, and
differentiation of epithelial cells. Current models of how sig-
naling may be accomplished between stromal and epithelium
include transmission via diffusible substances, via the extracellu-
lar matrix, and via direct cell–cell contact. Growth factors and
organ specific paracrine factors are potential candidates pro-
duced by the stromal cells that affect the endometrial epithelium
(29, 30). In this respect, it has been reported that endometrial
stromal cells from women with endometriosis secrete a greater
amount of IGF-I and -II (31) and hepatocyte growth factor (32).
Signaling through direct stromal–epithelial contact may also be
accomplished via interactions between complementary cell surface
adhesion molecules (33, 34).
The dynamics of the differentiation process for human
endometriotic proliferations can be studied only in cell culture.
Such approach should provide information about this process
in vivo, particularly about how changing protein synthesis accom-
panies changing cell structure. To date, little is known about
mechanisms controlling endometriotic cell differentiation in vitro.
Primary endometriotic cell cultures retain some aspects of differ-
entiation as a manifest of appropriate protein synthesis. Compar-
atively, eutopic endometrial cells induced to differentiate produce
domes, gland-like structures, polarized sheets, and spheroids (35).
Conversely, cultures of stromal-like cells derived from endometri-
otic tissues display a variety in morphology indistinguishable from
normal endometrial stroma, containing both fibroblast-like cells
and cells with more rounded shape (36). However, experimental
work suggests that endometriotic cells from peritoneal implants
have an innate proliferative abnormality compared to eutopic cells
in that they undergo more rounds of cell division and can be main-
tained in a stationary but functional state for longer periods of time
in primary culture.
ENDOMETRIOSIS IN TISSUE CULTURE: PHENOTYPE AND
GROWTH CHARACTERISTICS
Ectopic endometrial cells have been poorly investigated, mainly
due to the rare availability of endometriotic tissue required for
cell culture and the limited number of cells, particularly those
of epithelial phenotype. Long term culture of endometriotic cells
appears to be a reliable method to study the proliferative charac-
teristics, the cellular capacity for differentiation, and the nature of
the biologic products released.
So far, establishment of human endometriosis derived perma-
nent cell lines were exceptionally successful. Two recently described
in vitro models, including the FbEM-1 cell line (37) and cell
lines obtained after immortalization of endometriotic cells with
simian virus 40 (38), may represent a valuable material for further
studies of endometriotic cell growth and differentiation. How-
ever, the proposed in vitro cell models have their limitations since
endometriotic lesions are histologically complex containing both
glandular and stromal elements. Thus, immortalized cell lines with
one cell type, usually exhibiting features of undifferentiated cells,
do not accurately represent the in vivo situation.
In an effort to learn more about endometriotic cell growth
and differentiation, a cell culture model from different types of
endometriotic lesions including ovarian cysts, peritoneal implants,
and deep infiltrating endometriosis was successfully established
in the author’s laboratory. Endometriosis cultures are in gen-
eral prepared from biopsies from the various lesions as essentially
described (37) with some modifications.
Briefly, the fragments obtained at surgery are rinsed, minced,
and digested with collagenase (2 mg/ml) at 37°C in 5% CO2 dur-
ing 120 min. Epithelial glands are separated from stromal cells,
blood cells, and debris by serial filtration using narrow gage
sieves (45µm). Thereafter, the glands are washed from the sieves
and allowed to proliferate in Dulbecco’s modified Eagle medium
supplemented with 10% fetal calf serum and antibiotics. In sep-
arate experiments, stromal cells from the collagenase digested
endometriotic tissues are allowed to adhere to the culture flasks
and maintained in vitro following the same culture procedures.
The primary cultures obtained from the peritoneal biopsies and
from the chocolate cyst wall contain mostly mixed cell populations
variable in their size and in their morphology. Within 1 week, small
foci consisting of rather small spindle or polygonal cells appear
among the loosely proliferating epithelial-like cells and gradually
increase in size. After 3–4 weeks in culture, the cellular monolayer
is successfully passaged in vitro at a density of 2× 105 cells/ml.
The cultured stromal cells from both endometriotic implants
and the endometrioma wall appear as adherent fibroblast-like cells,
their doubling time being approximately 9 days. These stromal ele-
ments usually proliferate as elongated cells, densely packed, and
reach confluence in about 10–14 days. An aspect on phase contrast
microscopy of an endometriotic gland from a peritoneal implant
in primary culture giving rise to growing epithelial-like cells and
third passage of culture derived from an ovarian endometrioma is
presented in Figure 1.
To determine if the cultured endometriotic cells retain specific
epithelial markers, immuno-cytochemistry is routinely performed
using a panel of specific antibodies. For immunostaining, the
endometriotic cells cultured either in tissue culture chamber slides
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FIGURE 1 | Phase contrast microscopy of a primary culture of a
fragment from ovarian endometrioma (A). Note presence of an
endometriotic gland giving rise to a monolayer of epithelial-like cells (A).
In (B), aspect of elongated fibroblast-like cultured cells obtained from the
stromal component of a large peritoneal endometriotic implant (B).
(Labtek) or prepared as cytocentrifuge smears are fixed in 4%
paraformaldehyde or in cold acetone (10%), rinsed in PBS, and
incubated with the primary antibody. Monoclonal and/or poly-
clonal antibodies are revealed using rabbit anti-mouse or goat
anti-rabbit IgG peroxydase conjugated antibodies (Dako, Den-
mark) according to standard methods. Control slides are incu-
bated with normal mouse serum to replace the specific monoclonal
or polyclonal antibodies.
The results of the immuno-histochemical staining of both
epithelial and stromal endometriotic cells with specific mono-
clonal and polyclonal antibodies are summarized in Table 1.
Among the epithelial markers, cytokeratin expression remained
one of the most specific characteristics of the cultured cells. The
anti-cytokeratin antibody detecting cytokeratin 8, 18, and 19 pro-
duce cytoplasmic immunolabeling of the majority of epithelial
endometriotic cells from various passages (Figure 2). These cells
were negative for factor VIII-related antigen, indicating no conta-
mination with endothelial cells. More than 40% of the cells were
immunoreactive with the anti progesterone receptor (PR) anti-
body showing brown nuclear stain produced by the diaminobenzi-
dine (DAB) colorimetric reaction (Figure 2). Conversely, less then
15% were stained with anti androgen receptor antibody while only
weak immunostaining was obtained for estrogen receptor (2–5%).
For comparison, both cytokeratins and vimentin were expressed
in endometriotic stromal cells. Thus, most of the phenotypic fea-
tures of the normal endometrium are retained in the cultured
endometriotic cells (Figure 2).
Concerning the differentiation capacity, experiments were per-
formed to determine whether the cultured epithelial and stro-
mal endometriotic cells undergo changes after treatment with
the estradiol metabolite 2-Ethoxyestradiol and medroxyproges-
terone acetate (MPA). Phase contrast microscopy indicated that
cells cultured in the absence of steroids remained growing until
confluence. For cultures grown in medium supplemented with
1% of FCS, addition of with 2-Ethoxystradiol (1µM) resulted
in strong inhibition of cell growth and appearance of morpho-
logical changes, i.e., the cells became large with appearance of
cytoplasmic projections (Figure 3). In contrast, addition of MPA
(1µM) resulted in an approximately twofold stimulation of the
Table 1 | Phenotype of endometriotic cell cultures.
Antibody
used
Specificity Sourcea Epithelial
cellsb
Stromal
cellsb
CK (5D3) Cytokeratins 8, 18, 19 Boehringer 60 15
V9 Vimentin Dako 30 75
E29 EMA Dako – –
Factor VIII vWF Dako – –
IOT2 HLA cl.I Immunotech 40 35
CD3 (UCHT1) T cells Dako – –
CD20 (B-Ly) B cells Dako – –
CD45 RB T, B, Mo, Mf, Gr Dako – –
R (B-30) Progesterone receptor Santa Cruz 40 21
AR (C-19) Androgen receptor Santa Cruz <10 10
ER (H-20) Oestrogen receptor Santa Cruz – 24
DE-R11 Desmin Dako – 2
CIV22 Collagen IV Dako – –
CEA (II-7) Carcinoembryonic
antigen
Dako – –
OC-125 CA-125 Dako – –
CA-125= carcinoma antigen-125; EMA=epithelial membrane antigen;
vWF= vonWillebrandt factor; HLA=human leukocyte antigen.
a,bPercentage of positive epithelial and stromal cells.
cell growth. When cultured in Matrigel for 96 h, the number of
MPA-treated cells was considerably greater than that of untreated
cells. Occasionally, some of the cells exhibit morphological changes
and develop a polygonal appearance (not shown). This phe-
nomenon may be explained by the increased level of adhesion
molecules in MPA-treated endometriotic cells promoting the
aggregation (33, 34).
CYTOGENETIC AND MOLECULAR GENETIC ANALYSIS OF
ENDOMETRIOSIS
Most genetic changes occur in somatic cells, but some occur as
germ line defects that can result in an inherited predisposition to
endometriotic development. In this context, convincing evidence
in favor of a genetic basis for endometriosis is provided by several
studies sowing that the prevalence of the disease is higher in the
first-degree relatives of affected women than in controls thought
to be representative of the general population (39–43).
At the tissue level, cytogenetic, molecular genetic, and mole-
cular cytogenetic techniques have been applied to endometrio-
sis and have lead to the identification of consistent somatic
genetic alterations. Altogether, these findings strongly suggest exis-
tence of genomic aberrations in endometriotic tissues probably
related to distinct putative genes involved in development of the
disease.
CHROMOSOMAL ANOMALIES OBSERVED IN ENDOMETRIOTIC CELLS
To date, conventional cytogenetic studies have been poorly infor-
mative because of the rare availability of endometriotic tissue
required for cell culture and the limited yield of endometriotic
cells. No specific chromosomal abnormalities have been identified
by conventional cytogenetic analysis applied to date, to a total of
73 published cases of endometriotic lesions (44, 45). The limited
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FIGURE 2 | Immuno-cytochemical localization of cytokeratin (A),
vimentin (B), estrogen receptor (C), progesterone receptor (D), androgen
receptor (E) and factor VIII (F) proteins in cultured endometriotic cells
(second passage). The culture was established from a large peritoneal
implant (black lesion). Note presence of large polymorphic adherent cells
growing in monolayer. Original magnification ×400; in B,C,D,E,F (× 280).
FIGURE 3 | Aspect on phase contrast microscopy of untreated (A) and endometriotic cells treated with 2-Ethoxyestradiol (1 mM) during 24 h (B).
A striking morphological change was obtained after 12 h of treatment. The 2-Ethoxyestradiol induced decrease of DNA synthesis by 68% after 48 h of treatment
(BrDU incorporation).
information yielded by conventional karyotypic studies reflects
two factors; the difficulties specifically related to endometriotic
tissues and those inherent to the technique. In fact, culture of
pure endometriotic cells is hampered by the mixture of epithelial
and stromal cells in addition to inflammatory infiltrate containing
fibroblasts and histiocytic cells. Alternatively, the predominantly
normal karyotype seen in endometriotic lesions may be due to
resolution limits of karyotyping, with any changes present being
submicroscopic. Moreover, there may be overgrowth of normal
cells or selection in vitro against aneuploid cells. The evidence for
the latter comes from a study where the FISH was performed on
direct preparation revealing clonal aberrations and aneuploidy of
several chromosomes (46). This selection against aneuploid cells
may be a result of the methods used in preparation of the tissue.
It is noteworthy that collagenase, used to disrupt the lesion prior
to culture, results in loss of the aneuploid population that is not
seen when mechanical disruption alone is used. Despite the diffi-
culties of cytogenetic analysis discussed above, it nevertheless has
an important role to play in understanding of endometriosis. It is
important to emphasize, for example, that cytogenetic analysis is
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the only technique among those reviewed here that has the ability
to identify novel chromosomal translocations.
To investigate the chromosomal structure of the different types
of endometriotic lesions, we performed conventional karyotype
analysis of a series of seven endometriotic samples obtained from
patients with advanced stage disease. In strictly defined culture
conditions, increased percentage of aberrant metaphases showing
aneuploidy, dicentric chromosomes, endomitoses, and chromoso-
mal pulverization were detected in five of seven studied samples by
RHG-banding (Figure 4). These results were further extended by
multicolor fluorescence in situ hybridization analysis (FISH) with
painting probes for chromosomes 1, 6, 7, 8, 11, 12, 17, and 22.
FISH analysis with painting probe for chromosome 17, demon-
strated presence of three copies of that chromosome in 17% of the
analyzed metaphases in one ovarian endometrioma. In contrast,
loss of chromosome 17 was detected in 2 cases of 7 studied. Loss of
the q arm of chromosome 22 was detected in 3 cases (not shown).
Similar data were previously reported by Shin et al. (46) in one case
of four endometriotic samples studied. Thus, it could be hypothe-
sized that at least chromosomes 1, 16, 17, and 22 exhibit structural
aberrations containing genes that might play a role in the devel-
opment and/or progression of endometriosis. In this context, it
should be underlined that endometriotic tissue sampling and cul-
ture conditions are of a major importance in successful detection
of aberrant metaphases.
Loss of heterozygosity
Only a limited number of loss of heterozygosity (LOH) studies
have been conducted using DNA from histologically homoge-
neous endometriotic tissues. Recent molecular allelotyping work
has detected somatic genetic changes, distributed along several
chromosomes including chromosome 9p, 11q and 22q in 11 of
40 (28%) examined endometriotic samples (47). When more
informative loci markers were applied, allelic imbalances were
revealed in 82% of the endometriotic lesions diagnosed simultane-
ously with ovarian carcinoma (48). However, allelotyping studies
are limited to analyzing specific regions of the genome for exam-
ple detecting loss of part of a chromosome arm in a set of lesions.
They are also limited by the need to have endometriotic tissue with
minimal normal contaminating tissue and normal tissue from the
same patient to serve as a control. Nevertheless, these studies were
remarkable enough to point out that tumor suppressor gene (s)
inactivation may play a role in the development of endometriosis.
Fluorescence in situ hybridization
In general, FISH analysis has revealed more clonal aberrations than
conventional cytogenetic analysis in a number of altered tissues.
This approach has the advantage that culturing of endometri-
otic cells is unnecessary and eliminates the problems of tissues
heterogeneity. Performed on interphase nuclei in severe/advanced
stage endometriosis, higher frequency of monosomy for chromo-
some 16 and 17 and increased number of cells with trisomy 11
were recently reported (46, 49). The limitations of studies using
FISH strategy is that only centromeric probes have been used
and not all chromosomes have been investigated. The informa-
tion gained using centromeric probes is extrapolated to the whole
chromosome, an assumption which may not be accurate.
GENETIC ABERRATIONS IN ENDOMETRIOSIS DETECTED BY
COMPARATIVE GENOMIC HYBRIDIZATION
Comparative genomic hybridization (CGH) is a molecular cyto-
genetic method able to discover and map genomic regions for
chromosomal gains and/or losses in a single experiment (50).
Regions showing an increased copy number (gain or amplifi-
cation) may harbor dominant oncogenes, whereas regions with
a decreased copy number (loss) may contain tumor suppressor
FIGURE 4 | Representative metaphase spreads obtained from four
different endometriotic lesions. Note presence of structural
chromosomal alterations expressed as aneuploid metaphase with
homogeneous staining region (HSR) in (A), dicentric chromosomes (DICs)
(B), double minute chromosomes D-MIN (C), premature centromeric
disjunctions (D).
www.frontiersin.org May 2014 | Volume 1 | Article 16 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bouquet De Jolinière et al. Endometriosis, pathogenesis, genetic approach, profile
FIGURE 5 | DNA was extracted from a tissue section of a large peritoneal endometriotic implant with presence of an endometriotic gland containing
papillary projections [Hematoxylin Eozin stained (A), and from a gland of tissue section from rectovaginal endometriotic nodule (B)].
genes. In this regard, the CGH approach has been success-
fully applied in studies of solid tumors including endometrial
(51) and ovarian carcinomas (52), and ovarian carcinoma cell
lines (53).
By means of CGH, we screened primary endometriotic lesions
for chromosomal gains and/or losses in a series of patients with
advanced stage disease. The study was performed on native, non-
amplified DNA extracted from manually dissected endometriotic
tissues (Figure 5). Recurrent gene copy number alterations were
found in 15 of 18 (83%) of cases with advanced stage endometri-
otic lesion indicating clonal genetic changes. Losses which pre-
dominated over gains showed clustering at certain chromosomal
regions suggesting a recurrent non-random pattern of chromo-
somal alterations. Imbalances were not found in three cases, yet
existence of balanced reciprocal translocations, very small chro-
mosomal imbalances or mutations can not be excluded since such
alterations are not detectable by CGH.
The average number of copy alterations in our series of
endometriotic tissues was 3.1 per lesion, which is low compared
to malignant tissues (52). The DNA copy number abnormali-
ties were not related to the histological type or to the site of
the endometriotic lesion. Remarkably, low frequencies of somatic
genetic changes by CGH analysis were demonstrated in other
benign proliferations (54, 55).
The most common regions of loss of genomic material were
located on 1p involving at least the 1p32–36 (50%), 5p (33%), 6q
(27%), 7p14-p22ter (22%), 16qter (22%), and 22q12.3-qter (50%)
segments (Table 2; Figure 6). The other less common copy num-
ber changes included loss involving chromosome arms 9q (22%),
16q (22%), and 17q, found in one case. Underrepresentation of
1p was recurrently found in 9 of 18 studied cases. DNA sequences
losses were restricted to the 1p36 band in three cases; the remaining
six were larger deletions. Deletions of chromosome 1 were partic-
ularly common in all types and stages of endometriotic tissues
including the peritoneal implants, endometriomas, and umbilical
nodules. Gains were less commonly found and were localized on
chromosomes 6q and 17q in 2 cases (Table 2).
Table 2 | Genetic aberrations in endometriotic tissues detected by
comparative genomic hybridization.
Case (*) Stage Chromosome imbalances
1 IV dim (1p, 7p, 22q)
2 IVa dim (5p12-ter, 16q, 17qter, 22q)
3 IV dim (1p36-ter, 16q, 22q)
4 III dim (1p, 6q, 7p, 21q, 22q)
5 IVa enh (7q)
6 IV None
7 III None
8 IVa dim (1p36-ter, 6q, 9qter, 19q)
9 IVa dim (7)
10 IVa dim (1p, 5p, 8p, 11p, 16q, 17p)
11 IVa enh (1q), dim (5p, 9q, 16q)
12 IVb dim (1p36-ter, 2p, 5p, 6q, 7q, 11q)
13 IVa dim (3q, 5p, 6q, 9q, 22q)
14 IV dim (1p, 7p, 22q)
15 IVb enh (6q), dim (2p21,5p,7p, 9q, 12q,19q,22q)
16 IV None
17 IV dim (1p, 6q, 22q)
18 IV enh (17q), dim (1p, 22q)
*Large peritoneal implants (case 1–6); umbilical endometriotic nodules (case 7–8);
ovarian endometriomas (case 9–18).
Deletions of the short arm of chromosome 1 are of particular
interest since they were found in 50% of the cases with advanced
stage endometriosis. Chromosome 1p is known to harbor puta-
tive tumor suppressor genes associated with a variety of tumors
including neuroblastomas, pheochromocytomas, melanomas, and
carcinomas of the liver, breast, and colon (56) although, to date,
none of these gene (s) has been cloned. They include ID3,CDC2L1,
DAN, PAX7, E2F2, TNFR2, and TCEB3 (57).
Other relevant copy number losses indicative of chromo-
somes where tumor suppressor genes reside were mapped to
chromosomes 5p, 6q, and 22q. Copy number changes on both
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FIGURE 6 | Complete CGH analysis of one large endometriotic
peritoneal implant presented in (A). Compilation of fluorescence ratio
profiles from 10 different metaphases was used to calculate the average
ratio profiles of this sample. As shown, copy number losses are
distributed along chromosomes 1p, 7p and 22q. DAPI staining on
the left, and digitized fluorescent image on the right. More detailed
representation of the deleted chromosomal segments located on
chromosomes 1, 7 and 22 (B).
chromosomes 5p and 6q were detected in approximately one third
of the endometriotic cases studied. Previous allelotyping studies
have reported high percentage of LOH using markers located at 5p
and 6q chromosomal segments in numerous human malignancies.
For example, consistent copy number losses on 5p were detected
in papillary thyroid cancer (58), human male germ tumors (59),
and in childhood acute lymphoblastic leukemia (60). Concerning
the chromosome 6 it has been suggested that a putative tumor
suppressor gene located on the 6q arm is involved in develop-
ment of ovarian carcinoma (61). A potential candidate tumor
suppressor gene for this region may be the superoxide dismu-
tase gene 2 (SOD2) gene located on 6q25. High frequencies of
LOH encompassing the SOD2 gene have been shown in ovarian
carcinoma (61).
Another region found recurrently deleted in two endometri-
otic peritoneal implants and two large ovarian endometriomas is
located on the long arm of chromosome 16. Reduced copy num-
ber on 16q may facilitate inactivation of the cell adhesion molecule
E-cadherin (62) and the cell adhesion regulator CAR gene product
(63). Loss of DNA sequences on 16q could also be related to
the decreased expression of E and N-cadherin molecules recently
reported in a series of endometriomas, cystadenomas, borderline,
and carcinomas of the ovary (64).
A striking finding is the underrepresentation of chromosome
22 seen in 50% of the cases analyzed. DNA copy number loss
interpreted as monosomy of chromosome 22 has been described
notably in various neoplasms, including ovarian carcinoma (65),
meningioma (66), and mesothelioma (67). One candidate for the
tumor suppressor gene in chromosome 22q is neurofibromatosis
type 2 (NF2) gene at 22q12 (68).
The molecular cytogenetic data identified by CGH in primary
endometriotic lesions correspond in part to previous molecular
allelotyping findings (47, 48). Our results highlight several novel
regions located on chromosomes 1p, 6q, and 22q that might
harbor single or multiple tumor suppressor genes involved in
pathogenesis of endometriosis. Altogether, the non-random dis-
tribution coupled with the subchromosomal localization of the
genetic alterations strongly supports the idea that these abnor-
malities are relevant to and associated with the endometriotic
process.
OCCURRENCE OF CHROMOSOMAL INSTABILITY IN
EDOMETRIOTIC LESIONS
It is defined as an alteration of the chromosome constitution
occurring in various pathological conditions:
- Fundamental property of neoplastic cells (most malignant and
benign tumors) (69).
- Precancerous lesions (dysplasia, leucoplasia, and cystically
altered tissues).
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- Chronic inflammatory conditions.
- Infectious diseases.
- Diseases induced by viruses (herpes, HPV, EBV,. . .).
The genomic instability appears in two different types:
- Chromosomal alterations in non-neoplastic precursor lesions
and mutation of the P53 gene.
- Errors in DNA replication detected by microsatellite instability
(deficiency in DNA mismatch repair mechanism).
We have observed (37, 69) such an instability in our studies with
presence of chromosome copies number changes, chromosomal
deletions, translocations, presence of endomitoses, premature cen-
tromeric disjunctions and presence of micronuclei (Figures 4 and
6A,B).
The loss of either essential genes (TSGs) or even entire chro-
mosomes, explain the high invasive potential of the endometriotic
cells. Genomic alterations (rearrangements) initiated for instance
by telomere dysfunction can be a primary event that facilitate
endometriosis initiation and spread (70).
A POSSIBLE PATHOGENIC ROLE OF EMBRYONIC DUCT
REMNANTS IN FEMALE FETAL REPRODUCTIVE TRACT IN
ENDOMETRIOSIS AND OVARIAN TUMORS
The theory of transformation of the vestigial tissue of Müllerian
or Wolfian origin and the celomic metaplasia theory can explain
the origin of distinct entities: for instance endometriotic lesions
as well as development of particular types of ovarian neoplasms.
In the same context, a recent study has proposed the fetal ori-
gin of endometriosis that could develop on the basis of altered
migration of primitive endometrial tissue during embryogenesis
(71). These authors assessed that the incidence of the dislocated
embryonic structures in fetuses is similar to that of endometriosis
occurring in the adult female population. In the same direction,
relationship between endometriosis and malignancies arising in
gonadal and extra gonadal endometrial implants become sup-
ported by several clinical pathologic and molecular investigations.
These studies suggested that histogenetically, endometriosis rep-
resents an important site of origin of ovarian and other pelvic
malignancies. It was described that such neoplasms are constituted
of clear epithelial cells and tend to be detected in earlier stages,
their prognosis being more favorable. In addition, embryonic duct
remnants were often microscopically observed adjacent to ovarian
tumors as well as close to pelvic endometriotic lesions suggesting
a pathogenetic relationship (7).
In a previous study, we evaluated the incidence and the anatom-
ical location of displaced endometrial tissue in the reproductive
tract in seven female fetuses. Serial sectioning of the reproductive
organs was realized followed by immuno-histochemical analysis
of tissue areas containing ectopic glands and embryonic cell rests
(Table 3; Figures 7 and 8).
We have compared these results with those of two germ
cells tumors, the young and adult forms using exclusively an
immuno-histochemical analysis.
It was observed that the anatomical and the phenotypic features
of the misallocated tissue components recall some pathologi-
cal characteristics of both benign and malignant gynecological
conditions (72).
HOW ANDWHY TO DEFINE THE EVOLUTIVITY?
The actual classification used around the world is only anatomic,
with adjunction recently of pain and deep lesions (76). But, we
have observed with the immuno-histochemical analysis that the
proliferation depend at first on the presence or not of hormonal
receptors (PR; ER) and oncogenes.
In addition, in this study, the proliferation is shown with the
lesions having lost their chromosomal stability. All these lesions
have genomic abnormalities. Thus, when endometriotic cells cul-
tured from these lesions (PR< 30% or PR-; ER-) are treated
with progestins, an increase in the proliferation curve is observed
(37) that is correlated with a clinical dissemination in the pelvis
and possibly with the occurence of “metastases” outside of the
abdominal cavity.
There are no correlations between the size of lesions and
the severity of the disease (Figure 9). Consequently, all lesions
Table 3 | Summary of the percentages of immunoreactive cells in embryonic ducts and the surrounding stroma present in various locations of
the fetal reproductive tract.
Gestational age (weeks) EMA* Cytokeratin 7* ER* PR* Vimentin* CD10*
D St D St D St D St D St D St
18 32 – 2 – 10 – 19 11 35 4 2 55
19 52 – – – 12 – 21 6 26 9 – 38
20 38 – – 3 18 3 13 8 34 13 – 42
21 43 – – – 13 – 19 4 22 20 – 39
22 46 – – – 23 – 31 13 25 6 – 44
32 0 0 0 – 0 0 0 0 0 0 0 0
36 53 1 11 1 16 1 44 9 53 32 4 64
Mean value** 264 1 13 4 92 4 147 51 195 84 6 282
D, embryonic duct; St, Stromal layer; *percentage of cells expressing the indicated marker; mean value** [represents a ratio of the number of counted cells (200)
divided by the number of immunolabeled cells].
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FIGURE 7 | Hematoxylin and eosin stained sections with areas of
ectopic endometrial glands and embryonic ducts. Histological
appearance of ectopic glands and stroma observed (insert at higher
magnification) in fetal uterine wall (A). Presence of embryonic ducts
located in the broad ligament (B), under the fallopian tube serosa
(C) and ducts located in the ovarian ligament (D). Note presence of a
stromal component surrounding the duct residues in a, b, c, and d.
Scale bars, and 100µm.
removed by surgery must be tested by a phenotypic and genotypic
analysis.
An immunohistochemical profile of the lesions (Endometri-
ogram*) should be defined in a similar way as the procedure used
to molecularly classify the breast cancer. Using this strategy, the
medical treatment can be decided including the IVF technology in
case of infertility.
Thus, larger prospective randomized studies should be carried
on in the future with the main basic concept to introduce the most
apporpriate algorithm for therapeutic decision.
CONCLUSION AND PERSPECTIVES
Substantial progress has been made in the last few years to under-
stand better the etiologies, pathogenesis, and means to treat
endometriosis. This field of investigation is supposed to make
greater advances in the near future. From the collected molec-
ular data, it is evident that one or several genes may be disrupted
by mutations or loss of DNA sequences in this condition. Loss of
some protein functions may effect the regulation of several emerg-
ing down stream pathways, including the EGFR-axis, E-cadherin
dynamics, transcriptional regulation, cell cycle regulation (pro-
liferation/apoptosis), and cell adhesion. Divergences from mature
endometrial epithelium to endometriotic epithelium must involve
abnormal gene expression, which may directly cause or reinforce
the alterations caused by changes of one or several genes under-
going germinal alterations. Within this context, the treatment
strategies of endometriosis centered mainly toward ovarian func-
tion suppression and indirect limitation of cell growth and activity
of endometriosis remain insufficient (73, 74).
Future studies should concentrate on modifying and extending
the use of the molecular biology techniques. Cytogenetic analysis
with improved culture techniques of endometriotic tissue, capable
of simulating the normal endometriotic environment, may help
to prevent selective in vitro growth pressures. CGH and cDNA
microarray studies has only been used to date on a limited number
of primary endometriotic samples, yet has given us important
informations (41, 75). Gene expression profiling, allelotyping, and
FISH studies need to investigate the various types of endometri-
otic samples and more regions of the genome. As techniques are
improving and examination of archival material is now possible
it should be easier to correlate clinical data with the phenotypical
features and genotype of primary lesions. This will certainly yield
informations important for the early diagnosis and prognosis of
patients.
Finally, the anatomical and the immuno-histochemical fea-
tures of the ectopic organic structures identified in fetal female
reproductive tract suggest that endometriotic as well as neoplastic
disease in adult women may develop on the basis of misplaced
endometrial glands and/or embryonic cell remnants.
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100µm in (B–H).
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